Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 222

Sort by

Sort Order Select

Journal Articles

FXII inhibition: multipronged benefits

Helen Philippou

Blood (2021) 138 (2): 107–109.

https://doi.org/10.1182/blood.2021011032

Published: 2021

Journal Articles

CYT-0853, a Novel RAD51 Inhibitor, Modulates Immunoregulatory B-Lymphocytes

Tamar Aprahamian, PhD, ED Keniston, Jane Branca, Muneer G Hasham, PhD, Melinda Day, PhD, Kevin Mills, PhD

Blood (2019) 134 (Supplement_1): 2330.

https://doi.org/10.1182/blood-2019-131311

Published: 2019

Journal Articles

Prospective Controlled Monitoring of Hemlibra Prophylaxis Initiation in a Large Cohort of Hemophilia a Patients- Real World Data

Assaf Arie Barg, Tami Livnat, PhD, Tami Brutman-Barazani, Nurit Rosenberg, Ivan Budnik, MD PhD, Gili Kenet

Blood (2019) 134 (Supplement_1): 2397.

https://doi.org/10.1182/blood-2019-122010

Published: 2019

Journal Articles

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial

Amy Shapiro, Giancarlo Castaman, MD, Katarina Cepo, Lone Hvitfeldt Poulsen, Christian Hollensen, Tadashi Matsushita, Guy Young, MD, Silva Zupancic-Salek, Victor Jimenez-Yuste

Blood (2019) 134 (Supplement_1): 1139.

https://doi.org/10.1182/blood-2019-122809

Published: 2019

Journal Articles

Low-Grade Inflammation in Hemophilia

Lynn M Knowles, PhD, Hermann Eichler, Jan Pilch, MD

Blood (2019) 134 (Supplement_1): 1115.

https://doi.org/10.1182/blood-2019-125127

Published: 2019

Journal Articles

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Hermann Eichler, Pantep Angchaisuksiri, MD, Jan Astermark, MD PhD, Gary Benson, Katarina Cepo, Pratima Chowdary, MD, Ute Friedrich, PhD, Kaan Kavakli, Allison P Wheeler, MD, Johannes Oldenburg, MD PhD

Blood (2019) 134 (Supplement_1): 2417.

https://doi.org/10.1182/blood-2019-122300

Published: 2019

Journal Articles

Concizumab Subcutaneous Prophylaxis Improves Health-Related Quality-of-Life Measures in Patients with Congenital Hemophilia with Inhibitors: Phase 2 Trial Results

Xin Ying Lee, Katarina Cepo, Thomas Porstmann

Blood (2019) 134 (Supplement_1): 2419.

https://doi.org/10.1182/blood-2019-122827

Published: 2019

Journal Articles

Prevalence and Associated Factors for Arterial Hypertension in Adults Following Hematopoietic Stem Cell Transplantation

Claudia Marcela Chalela, MD, Juan Carlos Uribe, MD MSc, Maria Luna-Gonzalez, Angela María Peña, MD, Sara Ines Jimenez, MD, Luis Antonio Salazar, MD, Manuel Rosales, MD, Manuel Ardila-Baez, MD, Katherine Espinosa, MD, Julian Baez, MD, David Leonardo Reyes, MD, Juan Jose Rey, MD MSc, Sergio Serrano, MD MSc, Jose Sandoval-Sus, MD, Claudia Lucia Sossa, MD

Blood (2019) 134 (Supplement_1): 5689.

https://doi.org/10.1182/blood-2019-129321

Published: 2019

Journal Articles

Post-Transplant Maintenance Treatment with Ponatinib for Philadelphia Chromosome Positive Leukemia

Blood (2019) 134 (Supplement_1): 5694.

https://doi.org/10.1182/blood-2019-128031

Published: 2019

Journal Articles

Adeno-Associated Virus Mediated Delivery of a TFPI Antibody Restores Hemostasis in Mouse Model of Hemophilia

Swapnil Rakhe, MS, Reema Jasuja, PhD, Rajani Shelke, Anagha Sawant, Suryanarayan Somanathan, PhD, John E. Murphy, PhD, Debra D Pittman, MS

Blood (2019) 134 (Supplement_1): 3357.

https://doi.org/10.1182/blood-2019-130054

Published: 2019

Journal Articles

Maintenance Therapy with Decitabine after Allogeneic Hematopoietic Stem Cell Transplantation to Prevent Relapse of High Risk Acute Myeloid Leukemia

Yunju Ma, Changju Qu, PhD, Haiping Dai, Jia Yin, Zheng Li, Jia Chen, Huiying Qiu, Aining Sun, PhD, Miao Miao, Chengcheng Fu, Zhengming Jin, MD, Xiaming Zhu, Depei Wu, MD PhD, Xiaowen Tang

Blood (2019) 134 (Supplement_1): 3306.

https://doi.org/10.1182/blood-2019-124033

Published: 2019

Journal Articles

Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors

Shawn X. Sun, Yanyu Wu, Michael McDermott, Marjolijn van Keep

Blood (2019) 134 (Supplement_1): 2102.

https://doi.org/10.1182/blood-2019-124421

Published: 2019

Journal Articles

Incidence and Outcomes of Cardiovascular Disease in Hemophilia Patients: An Analysis of National Inpatient Sample Database

Rohit Kumar, MD, Shruti Bhandari, MD, Sunny R K Singh, MD, Sindhu Malapati, MD, Sharad Khurana, MDMSc, Kamila I. Cisak, MD

Blood (2019) 134 (Supplement_1): 2176.

https://doi.org/10.1182/blood-2019-127628

Published: 2019

Journal Articles

Prophylactic Treatment in People with Severe Hemophilia B in the US: An Analysis of Real-World Healthcare System Costs and Clinical Outcomes

Declan Noone, MSc, Gabriel Pedra, PhD, Sohaib Asghar, MSc, Jamie O'Hara, MSc, Eileen K Sawyer, PhD, Nanxin (Nick) Li, PhD

Blood (2019) 134 (Supplement_1): 2118.

https://doi.org/10.1182/blood-2019-126576

Published: 2019

Journal Articles

Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A

Alfonso Iorio, Monika Maas Enriquez, Heinz Delesen, Alexander Solms, Stacy E. Croteau, Erik Berntorp

Blood (2019) 134 (Supplement_1): 3637.

https://doi.org/10.1182/blood-2019-127046

Published: 2019

Journal Articles

Non-Canonical MYD88/TIRAP-Dependent Anti-Inflammatory Function of Pro-Coagulant Factor VIII

Sandra Mignot, Sandrine Delignat, PhD, Sebastien Lacroix-demaze, PhD, Christine Bole-Feysot, PhD, Sherine Tei, Ananthy Kiddinan, Olivier Hermine, MD PhD, Laurent Frenzel, MD PhD

Blood (2019) 134 (Supplement_1): 3638.

https://doi.org/10.1182/blood-2019-127504

Published: 2019

Journal Articles

Thrombin Generation Assay in Plasma from Hemophilia a Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC

Marianne Kjalke, PhD, Mads Kjelgaard-Hansen, Søren Andersen, Ida Hilden

Blood (2019) 134 (Supplement_1): 3639.

https://doi.org/10.1182/blood-2019-122301

Published: 2019

Journal Articles

Characterization of a Novel Human Factor VIIa Chimera with Increased Tissue Factor-Independent Activity for Emergency Hemostasis

Ammon Fager, MD PhD, Maureane Hoffman, MD PhD, Dougald Monroe, PhD

Blood (2019) 134 (Supplement_1): 3623.

https://doi.org/10.1182/blood-2019-124428

Published: 2019

Journal Articles

Next-Generation FVIII Mimetic Shows Superior Effect in a FIX- and Fx-Humanized Mouse Model In Vivo

Carsten Dan Ley, PhD, Thomas Lindebo Holm, PhD, Daniel Elenius, PhD, Heidi Lindgreen Holmberg, PhD, Jais Rose Bjelke, PhD, Mette Loftager, PhD, Mette B Hermit, PhD, Ida Hilden, Stine L Kjellev, PhDDVM

Blood (2019) 134 (Supplement_1): 3631.

https://doi.org/10.1182/blood-2019-128159

Published: 2019

Journal Articles

Clinical Study to Investigate the Efficacy and Safety of Wilate during Prophylaxis in Previously Treated Patients with Von Willebrand Disease (VWD)

Robert F. Sidonio, Jr., MD MSc, Bruce A. Schwartz, PhD

Blood (2019) 134 (Supplement_1): 4931.

https://doi.org/10.1182/blood-2019-128339

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

FXII inhibition: multipronged benefits

CYT-0853, a Novel RAD51 Inhibitor, Modulates Immunoregulatory B-Lymphocytes

Prospective Controlled Monitoring of Hemlibra Prophylaxis Initiation in a Large Cohort of Hemophilia a Patients- Real World Data

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Hemophilia a or B with Inhibitors: Results from explorer4, a Phase 2, Randomized, Open-Label, Controlled Trial

Low-Grade Inflammation in Hemophilia

Efficacy and Safety of Subcutaneous Prophylaxis with Concizumab in Patients with Severe Hemophilia a without Inhibitors: Results from the Phase 2 explorer5 Trial

Concizumab Subcutaneous Prophylaxis Improves Health-Related Quality-of-Life Measures in Patients with Congenital Hemophilia with Inhibitors: Phase 2 Trial Results

Prevalence and Associated Factors for Arterial Hypertension in Adults Following Hematopoietic Stem Cell Transplantation

Post-Transplant Maintenance Treatment with Ponatinib for Philadelphia Chromosome Positive Leukemia

Adeno-Associated Virus Mediated Delivery of a TFPI Antibody Restores Hemostasis in Mouse Model of Hemophilia

Maintenance Therapy with Decitabine after Allogeneic Hematopoietic Stem Cell Transplantation to Prevent Relapse of High Risk Acute Myeloid Leukemia

Cost-Effectiveness Model of Recombinant FVIII Versus Emicizumab Treatment of Patients With Severe Hemophilia A Without Inhibitors

Incidence and Outcomes of Cardiovascular Disease in Hemophilia Patients: An Analysis of National Inpatient Sample Database

Prophylactic Treatment in People with Severe Hemophilia B in the US: An Analysis of Real-World Healthcare System Costs and Clinical Outcomes

Correlations between von Willebrand Factor Antigen Levels and Factor VIII Pharmacokinetics Are Similar across Different FVIII Products in Patients with Severe Hemophilia A

Non-Canonical MYD88/TIRAP-Dependent Anti-Inflammatory Function of Pro-Coagulant Factor VIII

Thrombin Generation Assay in Plasma from Hemophilia a Patients with or without Inhibitors on Concizumab Prophylaxis: Spiking with rFVIIa or aPCC

Characterization of a Novel Human Factor VIIa Chimera with Increased Tissue Factor-Independent Activity for Emergency Hemostasis

Next-Generation FVIII Mimetic Shows Superior Effect in a FIX- and Fx-Humanized Mouse Model In Vivo

Clinical Study to Investigate the Efficacy and Safety of Wilate during Prophylaxis in Previously Treated Patients with Von Willebrand Disease (VWD)

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only